Malignant tumors are one of the leading causes of death which impose an increasingly
heavy burden on all countries. Therefore, the establishment of research models that closely …

Glioblastoma multiforme (GBM) is the most common adult primary brain tumor. The standard
clinical treatment of GBM includes a maximal surgical resection followed by concomitant …

Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of
maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that …

Glioblastomas (GBMs) are the brain tumors with the highest malignancy and poorest
prognoses. GBM is characterized by high heterogeneity and resistance to drug treatment …

In glioblastoma, a mesenchymal phenotype is associated with especially poor patient
outcomes. Various glioblastoma microenvironmental factors and therapeutic interventions …

The blood–brain barrier is often altered in glioblastoma (GBM) creating a blood–brain–tumor
barrier (BBTB) composed of pericytes. The BBTB affects chemotherapy efficacy. However …

As a life-threatening chronic disease, cancer is characterized by tumor heterogeneity. This
heterogeneity is associated with factors that lead to treatment failure and poor prognosis …

Glioblastoma organoids (GBOs) serve as a powerful and reliable tool to study glioblastoma
stem cells (GSCs) and glioblastoma (GBM). GBOs can be derived from different materials …

Glioblastoma (GBM) is the most aggressive adult primary brain tumor with nearly universal
treatment resistance and recurrence. The mainstay of therapy remains maximal safe surgical …

Cancer remains as one of the highest challenges to human health. However, anticancer
drugs exhibit one of the highest attrition rates compared to other therapeutic interventions. In …